Novo, Catalent pulled, refiled US premerger antitrust filing April 2, triggering new 30-day wait, SEC filing says
MLex Summary: Obesity drugmaker Novo Holdings and Catalent — a contract development and manufacturing organization — withdrew and resubmitted their US premerger antitrust paperwork to federal authorities on April 2, restarting...To view the full article, register now.
Already a subscriber? Click here to view full article